Actinogen Medical Limited (ATGGF)
OTCMKTS · Delayed Price · Currency is USD
0.0250
0.00 (0.00%)
Oct 26, 2025, 8:00 PM EDT
Actinogen Medical Revenue
In the fiscal year ending June 30, 2025, Actinogen Medical had annual revenue of 5.49M AUD, down -44.73%. Actinogen Medical had revenue of 5.49M in the half year ending June 30, 2025, with 41.34% growth.
Revenue
5.49M AUD
Revenue Growth
-44.73%
P/S Ratio
19.75
Revenue / Employee
914.93K AUD
Employees
6
Market Cap
71.10M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 5.49M | -4.44M | -44.73% |
| Jun 30, 2024 | 9.93M | 5.04M | 103.18% |
| Jun 30, 2023 | 4.89M | 1.25M | 34.28% |
| Jun 30, 2022 | 3.64M | 1.66M | 83.47% |
| Jun 30, 2021 | 1.98M | -1.53M | -43.58% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |
Actinogen Medical News
- 6 months ago - Actinogen provides pivotal Alzheimer's trial enrolment update and other business news - Benzinga